Supt16h: A Potential Drug Target and Biomarker (G11198)

Target Name: SUPT16H

NCBI ID: G11198

Supt16h: A Potential Drug Target and Biomarker

Supt16h (NEDDFAC), a protein that belongs to the NEDD8 gene family, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug has piqued the interest of pharmaceutical companies.

Supt16h is a 16kDa protein that is expressed in various tissues and cells in the body. Its primary function is to catalyze the conversion of 2-acetyl-L-citrate (2-ACL) to 2-acetyl-L-lactic acid (2-ALA). This conversion is a critical step in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle, which is a central metabolic pathway that generates energy in the form of ATP.

Supt16h is a key enzyme in the TCA cycle, and its activity is regulated by various factors, including nutrients, hormones, and drugs. One of the well-known regulators of Supt16h is the protein p53, which is a tumor suppressor gene that plays a crucial role in preventing the development and progression of cancer.

Supt16h has been shown to be involved in various cellular processes, including cell growth, apoptosis, and metabolism. It has been shown to promote the growth of cancer cells, and to contribute to the development of neurodegenerative diseases. Its role in these processes has made it a potential target for drugs that can inhibit its activity or enhance its targets.

Supt16h has also been shown to play a role in the immune system. It has been shown to be involved in the regulation of immune cell function, and to contribute to the development of autoimmune disorders. This has led to the idea that Supt16h may be a useful target for drugs that can modulate immune cell function and prevent the development of autoimmune disorders.

In addition to its potential as a drug target, Supt16h has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be associated with the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This has led to the idea that Supt16h may be a useful biomarker for these diseases, and may be used as a target for drugs that can modulate its expression or activity.

Supt16h has also been shown to have potential therapeutic applications in the treatment of certain diseases. Its activity in the TCA cycle has been shown to be involved in the metabolism of certain nutrients, such as calcium and magnesium. This has led to the idea that Supt16h may be a useful target for drugs that can modulate its activity in these areas, and may be used to treat diseases that are caused by imbalances in these nutrients.

In conclusion, Supt16h is a protein that has been shown to play a critical role in various cellular processes in the body. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug and biomarker has piqued the interest of pharmaceutical companies. Further research is needed to fully understand its role in the body and its potential as a therapeutic agent.

Protein Name: SPT16 Homolog, Facilitates Chromatin Remodeling Subunit

Functions: Component of the FACT complex, a general chromatin factor that acts to reorganize nucleosomes. The FACT complex is involved in multiple processes that require DNA as a template such as mRNA elongation, DNA replication and DNA repair. During transcription elongation the FACT complex acts as a histone chaperone that both destabilizes and restores nucleosomal structure. It facilitates the passage of RNA polymerase II and transcription by promoting the dissociation of one histone H2A-H2B dimer from the nucleosome, then subsequently promotes the reestablishment of the nucleosome following the passage of RNA polymerase II. The FACT complex is probably also involved in phosphorylation of 'Ser-392' of p53/TP53 via its association with CK2 (casein kinase II)

More Common Targets